Dynamic Technology Lab Private Ltd lifted its position in shares of Morphic Holding, Inc. (NASDAQ:MORF – Free Report) by 39.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,354 shares of the company’s stock after acquiring an additional 3,764 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Morphic were worth $386,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Morphic by 48.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,421,820 shares of the company’s stock worth $78,394,000 after acquiring an additional 1,117,985 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Morphic by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,107,410 shares of the company’s stock worth $48,281,000 after acquiring an additional 200,772 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Morphic by 13.1% during the 4th quarter. Federated Hermes Inc. now owns 1,000,000 shares of the company’s stock worth $28,880,000 after acquiring an additional 115,975 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Morphic during the 4th quarter worth about $17,818,000. Finally, Silverarc Capital Management LLC boosted its stake in shares of Morphic by 134.2% during the 3rd quarter. Silverarc Capital Management LLC now owns 590,829 shares of the company’s stock worth $13,536,000 after acquiring an additional 338,520 shares in the last quarter. 94.25% of the stock is owned by hedge funds and other institutional investors.
Morphic Price Performance
MORF stock opened at $30.80 on Friday. Morphic Holding, Inc. has a 52-week low of $19.34 and a 52-week high of $63.08. The company’s 50-day simple moving average is $30.28 and its 200-day simple moving average is $30.25.
Morphic (NASDAQ:MORF – Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.05. On average, sell-side analysts forecast that Morphic Holding, Inc. will post -4.07 EPS for the current year.
Morphic Profile
(Free Report)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
Featured Stories
Want to see what other hedge funds are holding MORF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Morphic Holding, Inc. (NASDAQ:MORF – Free Report).
Receive News & Ratings for Morphic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Morphic and related companies with MarketBeat.com’s FREE daily email newsletter.